摘要
目的研究重组人p53腺病毒(rAd-p53)注射液联合顺铂+紫杉醇(TP)化疗方案对晚期宫颈癌(CC)患者疾病控制率及无进展生存时间的影响。方法以2019年10月至2021年10月该院收治的116例晚期CC患者为研究对象,根据治疗方案将患者分为对照组与联合组,每组58例。对照组采用TP化疗方案治疗,联合组采用rAd-p53注射液联合TP化疗方案治疗。比较两组疾病控制率,治疗前、治疗2个周期后欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)、癌症疲乏量表(CFS)评分,血清肿瘤标志物[鳞状细胞癌相关抗原(SCCA)、糖类抗原125(CA125)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)]、血清成纤维细胞生长因子受体4(FGFR4)、脊椎蛋白2(Spondin-2)水平,无进展生存时间。结果联合组疾病控制率为84.48%,高于对照组的67.24%(P<0.05);治疗2个周期后联合组EORTC QLQ-C30评分高于对照组(P<0.05),CFS评分低于对照组(P<0.05);治疗2个周期后联合组血清CYFRA21-1、CA125、CEA、SCCA、FGFR4、Spondin-2水平低于对照组(P<0.05);联合组无进展生存时间为7.12(95%CI:5.83~9.41)个月,长于对照组的5.77(95%CI:4.08~7.36)个月(P<0.05)。结论在TP化疗方案治疗晚期CC的基础上,加用rAd-p53注射液可有效控制疾病进展,缓解临床症状,降低血清肿瘤标志物水平,改善无进展生存时间。
Objective To investigate the effects of recombinant human adenovirus p53(rAd-p53)injection combined with TP chemotherapeutic regimen on the disease control rate and progression-free survival time in the patients with advanced cervical cancer(CC).Methods A total of 116 patients with advanced CC admitted to the hospital from October 2019 to October 2021 were selected as the research subjects and divided into the control group and combination group according to the treatment regimen,58 cases in each group.The control group was treated with the TP chemotherapeutic regimen,and the combination group adopted the rAd-p53 injection combined with TP chemotherapeutic regimen.The disease control rate,European Cancer Research and Therapeutic Tissue Quality of Life Scale(EORTC QLQ-C30)score,Cancer Fatigue Scale(CFS)score,serum tumor marker[squamous cell carcinoma-associated antigen(SCCA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)],serum fibroblast growth factor receptor 4(FGFR4)and Spondin-2 levels,progression-free survival time were compared between the two groups.Results The disease control rate in the combination group was 84.48%,which was higher than 67.24%in the control group(P<0.05).After 2 cycles of treatment,the EORTC QLQ-C30 score of the combined group was higher than that of the control group,and the CFS score was lower than that of the control group(P<0.05).After 2 cycles of treatment,the levels of serum CYFRA21-1,CA125,CEA,SCCA FGFR4 and Spondin-2 in the combination group were lower than those in the control group(P<0.05).The progression-free survival time in the combination group was 7.12(95%CI:5.83-9.41)months,which was higher than 5.77(95%CI:4.08-7.36)months in the control group(P<0.05).Conclusion On the basis of TP chemotherapeutic regimen in the treatment of advanced CC,the addition of rAd-p53 injection could effectively control the progression of the disease,relieve clinical symptoms,reduce the levels of serum tumor markers and improve the pro
作者
何小囡
吴玉
邱雪洲
HE Xiaonan;WU Yu;QIU Xuezhou(Department of Obstetrics and Gynecology,Fangcheng County Maternal and Child Health Care Hospital,Nanyang,Henan 473200,China)
出处
《检验医学与临床》
CAS
2023年第19期2868-2871,共4页
Laboratory Medicine and Clinic
关键词
重组人P53腺病毒注射液
TP化疗
晚期宫颈癌
疾病控制率
recombinant human adenovirus p53 injection
TP chemotherapy
advanced cervical cancer
disease control rate
